- Annexin på First North
- Finansiella rapporter
- Certified Adviser
Tillbaka till Pressmeddelanden
Annexin appoints Dr. Alain Thibault as Therapeutic Area Head of Oncology.
STOCKHOLM January 18, 2023
Annexin Pharmaceuticals AB (publ) announces that Dr. Thibault, a medical oncologist with extensive global experience leading novel compounds through clinical development, will join as a new team member and Therapy Area Head, Oncology.
Dr Thibault obtained his Medical Degree at McGill University Montreal, Canada and Board Certification in Oncology and Internal Medicine in the US. He has held management and specialist positions at Roche, J&J and Regeneron as well as Chief Medical Officer roles in biotech companies.
“Annexin is now entering the field of oncology and Dr Thibault´s expertise and leadership are both excellent and extremely important to us. Dr Thibault has already contributed to our Phase 2-/Proof of Concept-study design in immuno-oncology as a consultant and will bring additional leadership and valuable insights to our program both as an oncologist and an experienced drug developer. He is also well connected among potential pharma partners and investors.” says Anna Frostegård, MD, PhD, Chief Scientific and Medical Officer.
“The company´s lead drug candidate ANXV has a promising and differentiated profile in comparison to today´s blockbuster immuno-oncology drugs. ANXV is also amenable to chemical conjugation to bring otherwise toxic chemotherapy drugs to the tumor with reduced side effects. These opportunities may jointly bring clinical benefit to patients. I am excited to join the Annexin Pharmaceutical’s team in its development and partnering journey for ANXV in oncology.” says Dr. Thibault.
Dr. Thibault is based in France and assumes his new position immediately.
About Annexin Pharmaceuticals AB (publ)
Annexin Pharmaceuticals AB is a clinical stage biotechnology company world-leading in the Annexin A5 field for the treatment of various vascular diseases. The company’s biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is primarily intended for short term treatment of patients with injuries and inflammation of the blood vessels. The company has an extensive patent portfolio for the treatment of diseases that occur due to the damage and inflammation of the blood vessels. Annexin Pharmaceuticals has established and optimized a cell line for large-scale production of ANXV.
The Company is based in Stockholm, Sweden and listed on Nasdaq First North Growth Market, under the ticker ANNX. Redeye is the company´s Certified Adviser.
For further information, please contact:
Anders Haegerstrand, CEO, tel +4670 – 575 50 37
The information was submitted for publication at 10.00 on January 18, 2023.